JP2015528449A5 - - Google Patents

Download PDF

Info

Publication number
JP2015528449A5
JP2015528449A5 JP2015528817A JP2015528817A JP2015528449A5 JP 2015528449 A5 JP2015528449 A5 JP 2015528449A5 JP 2015528817 A JP2015528817 A JP 2015528817A JP 2015528817 A JP2015528817 A JP 2015528817A JP 2015528449 A5 JP2015528449 A5 JP 2015528449A5
Authority
JP
Japan
Prior art keywords
hepatitis
pharmaceutically acceptable
infection
composition
acceptable agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015528817A
Other languages
English (en)
Japanese (ja)
Other versions
JP6270846B2 (ja
JP2015528449A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2013/050377 external-priority patent/WO2014032176A1/en
Publication of JP2015528449A publication Critical patent/JP2015528449A/ja
Publication of JP2015528449A5 publication Critical patent/JP2015528449A5/ja
Application granted granted Critical
Publication of JP6270846B2 publication Critical patent/JP6270846B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015528817A 2012-08-30 2013-05-17 B型肝炎感染及びd型肝炎感染の治療方法 Active JP6270846B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261695040P 2012-08-30 2012-08-30
US61/695,040 2012-08-30
US201261703816P 2012-09-21 2012-09-21
US61/703,816 2012-09-21
PCT/CA2013/050377 WO2014032176A1 (en) 2012-08-30 2013-05-17 Methods for the treatment of hepatitis b and hepatitis d infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017217194A Division JP2018039834A (ja) 2012-08-30 2017-11-10 B型肝炎感染及びd型肝炎感染の治療組成物

Publications (3)

Publication Number Publication Date
JP2015528449A JP2015528449A (ja) 2015-09-28
JP2015528449A5 true JP2015528449A5 (cg-RX-API-DMAC7.html) 2016-06-02
JP6270846B2 JP6270846B2 (ja) 2018-01-31

Family

ID=50182316

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015528817A Active JP6270846B2 (ja) 2012-08-30 2013-05-17 B型肝炎感染及びd型肝炎感染の治療方法
JP2017217194A Pending JP2018039834A (ja) 2012-08-30 2017-11-10 B型肝炎感染及びd型肝炎感染の治療組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017217194A Pending JP2018039834A (ja) 2012-08-30 2017-11-10 B型肝炎感染及びd型肝炎感染の治療組成物

Country Status (23)

Country Link
US (4) US9133458B2 (cg-RX-API-DMAC7.html)
EP (1) EP2890403A4 (cg-RX-API-DMAC7.html)
JP (2) JP6270846B2 (cg-RX-API-DMAC7.html)
KR (2) KR102025679B1 (cg-RX-API-DMAC7.html)
CN (1) CN104837501B (cg-RX-API-DMAC7.html)
AU (1) AU2013308045B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015003985A2 (cg-RX-API-DMAC7.html)
CA (1) CA2883785C (cg-RX-API-DMAC7.html)
CL (1) CL2015000499A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150107A (cg-RX-API-DMAC7.html)
CU (1) CU20150018A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2015000041A (cg-RX-API-DMAC7.html)
EC (1) ECSP15007345A (cg-RX-API-DMAC7.html)
GT (1) GT201500046A (cg-RX-API-DMAC7.html)
IL (1) IL237173B (cg-RX-API-DMAC7.html)
IN (1) IN2015DN01087A (cg-RX-API-DMAC7.html)
MX (1) MX361522B (cg-RX-API-DMAC7.html)
MY (1) MY172785A (cg-RX-API-DMAC7.html)
NZ (1) NZ705730A (cg-RX-API-DMAC7.html)
PH (1) PH12015500361B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201501255PA (cg-RX-API-DMAC7.html)
TW (1) TWI620568B (cg-RX-API-DMAC7.html)
WO (1) WO2014032176A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100319T1 (it) 2012-05-18 2021-09-14 Replicor Inc Composizioni e metodi del complesso oligonucleotide chelato polipeptidico
SG11201501255PA (en) 2012-08-30 2015-03-30 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections
CN106659730A (zh) 2014-07-10 2017-05-10 里普利科股份有限公司 治疗b型肝炎和d型肝炎病毒感染的方法
WO2016030863A1 (en) * 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
US20160175245A1 (en) * 2014-12-19 2016-06-23 Mycotoxins Therapy, Llc Treatment of diseases associated with mold and mycotoxin exposure
CA2996722A1 (en) 2015-07-17 2017-01-26 Arcturus Therapeutics, Inc. Compositions and agents against hepatitis b virus and uses thereof
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
WO2017019891A2 (en) * 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
IL295692A (en) * 2016-01-08 2022-10-01 Arbutus Biopharma Corp Medical preparations and methods for treating jaundice b
JP7674628B2 (ja) * 2016-02-19 2025-05-12 イーアイティー・ファーマ・インコーポレイテッド インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
EP3634431A4 (en) * 2017-05-31 2021-06-23 Arbutus Biopharma Corporation THERAPEUTIC COMPOSITIONS AND METHODS OF TREATMENT FOR HEPATITIS B
TWI815887B (zh) * 2018-05-15 2023-09-21 美商愛彼特生物製藥股份有限公司 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
CN112534055A (zh) 2018-07-13 2021-03-19 豪夫迈·罗氏有限公司 用于调节rtel1表达的寡核苷酸
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
FI3898668T3 (fi) 2018-12-19 2023-11-28 Humabs Biomed Sa B-hepatiittivirusta neutraloivia vasta-aineita ja niiden käyttöjä
RS67553B1 (sr) 2018-12-20 2026-01-30 Humabs Biomed Sa Kombinovana hbv terapija
MX2022007908A (es) * 2019-12-24 2022-07-21 Hoffmann La Roche Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
CN114507663A (zh) * 2020-11-16 2022-05-17 浙江柏拉阿图医药科技有限公司 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030954A (en) 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US20040054156A1 (en) 1992-05-14 2004-03-18 Kenneth Draper Method and reagent for inhibiting hepatitis B viral replication
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
IL118625A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibodies
CA2254931C (en) * 1996-06-11 2007-04-10 Yeda Research And Development Co. Ltd. Human monoclonal antibodies to the hepatitis b surface antigen
DE19725803C1 (de) 1997-06-18 1999-02-11 Deutsches Krebsforsch HBV-gerichtete Antisense-Nukleinsäuren
CA2405502A1 (en) * 2000-03-29 2001-10-04 Georgetown University Method of treating hepatitis delta viral infection
BR0314236A (pt) 2002-09-13 2005-08-09 Replicor Inc Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
US20070027099A1 (en) * 2003-05-19 2007-02-01 Lin Marie C Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA)
EP2270162B1 (en) 2003-06-12 2018-10-03 Alnylam Pharmaceuticals Inc. Conserved hbv and hcv sequences useful for gene silencing
CN101084232A (zh) * 2004-10-19 2007-12-05 里普利科股份有限公司 抗病毒寡核苷酸
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
BR112012008865A2 (pt) * 2009-10-16 2019-09-24 Glaxo Group Ltd inibidores de hbv anti-sentido.
CA2746981A1 (en) * 2010-08-05 2012-02-05 Replicor Inc. Methods for inhibition of apolipoprotein h
BR112013003875B1 (pt) * 2010-08-20 2021-10-05 Replicor Inc Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos
US8921381B2 (en) * 2010-10-04 2014-12-30 Baruch S. Blumberg Institute Inhibitors of secretion of hepatitis B virus antigens
RS61447B1 (sr) 2011-04-21 2021-03-31 Glaxo Group Ltd Modulacija ekspresije virusa hepatitisa b (hbv)
EA024762B9 (ru) 2011-06-30 2017-04-28 Эрроухэд Рисерч Корпорейшн Композиции и способы ингибирования экспрессии генов вируса гепатита в
SMT202100319T1 (it) * 2012-05-18 2021-09-14 Replicor Inc Composizioni e metodi del complesso oligonucleotide chelato polipeptidico
AR091065A1 (es) 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
SG11201501255PA (en) 2012-08-30 2015-03-30 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections

Similar Documents

Publication Publication Date Title
JP2015528449A5 (cg-RX-API-DMAC7.html)
JP6922030B2 (ja) B型肝炎およびd型肝炎ウイルス感染の治療のための方法
TWI620568B (zh) 用於治療b型肝炎及d型肝炎感染之方法
Ma et al. Toward a functional cure for hepatitis B: the rationale and challenges for therapeutic targeting of the B cell immune response
JP2021533767A5 (cg-RX-API-DMAC7.html)
FI3837366T3 (fi) Hepatiitti b -viruksen (hbv) dsrna-ainekoostumuksia ja niiden käyttömenetelmiä
JP2013522302A5 (cg-RX-API-DMAC7.html)
WO2018087345A1 (en) COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
JP2017521433A5 (cg-RX-API-DMAC7.html)
JP2019533472A5 (cg-RX-API-DMAC7.html)
JP2015517504A5 (cg-RX-API-DMAC7.html)
Stein et al. Drug targets in hepatitis B virus infection
JP2024544532A5 (cg-RX-API-DMAC7.html)
De Clercq Interferon and its inducers—a never-ending story:“old” and “new” data in a new perspective
JP2022548652A (ja) コアタンパク質アロステリックモジュレータを使用してhbv感染を処置する方法
CN114057816B (zh) 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
Seto et al. Future prevention and treatment of chronic hepatitis B infection
Deanasa et al. The potential of antisense oligonucleotides (ASO) through inhalation based on gold nanoparticle (AuNP) delivery system in inhibiting SARS-CoV-2 replication and transcription
HK40065449A (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
Korkmaz et al. Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients
Niu Yanhua Ding, Jinfeng Lou, Hong Chen, Xiaojiao Li, Min Wu, Cuiyun Li, Jingrui Liu, Chengjiao Liu, Qingmei Li, Hong Zhang and Junqi Niu